Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
The DEA issues urgent warnings about fentanyl mixed with xylazine and medetomidine—animal sedatives that complicate overdose reversal and create new dangers for people who use drugs.
A new review reveals that the vast majority of adolescents with opioid use disorder are denied access to life-saving medications like buprenorphine, despite FDA approval and clinical guidelines supporting their use.
The Department of Veterans Affairs begins first government-sponsored study of MDMA-assisted therapy, enrolling 80 veterans in groundbreaking research on psychedelic treatment for co-occurring conditions.
FDA grants Breakthrough Therapy designation to LSD d-tartrate for generalized anxiety disorder, accelerating development of the first LSD-based psychiatric treatment and signaling regulatory openness to psychedelic therapies.
Philadelphia reports significant progress in reducing overdose deaths, particularly among Black residents who saw a 27% decrease, even as stimulant-related fatalities continue rising.
New NIH study reveals how cAMP signaling in brain neurons drives GLP-1 weight-loss effects, identifying a pathway to potentially extend treatment duration and break through patient plateaus.
SAMHSA's updated guidance states that medication-only models for opioid use disorder are inadequate, reigniting tensions between comprehensive care ideals and the practical realities of treatment access.
Attorney General Kris Mayes weighs legal action against Arizona counties allegedly misusing opioid settlement funds, highlighting growing tensions over pharmaceutical settlement accountability.
Machine learning models analyzing electronic health records can identify patients at high risk of fatal overdose up to 12 months before the event, offering a new tool for preventive intervention.